# Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)

> **NCT00672659** · PHASE2 · COMPLETED · sponsor: **PharmaNeuroBoost N.V.** · enrollment: 165 (actual)

## Conditions studied

- Depression

## Interventions

- **DRUG:** Citalopram + Pipamperone
- **DRUG:** Citalopram

## Key facts

- **NCT ID:** NCT00672659
- **Lead sponsor:** PharmaNeuroBoost N.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 165 (ACTUAL)
- **Last updated:** 2011-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00672659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00672659, "Pipamperone/Citalopram (PipCit)Versus Citalopram in the Treatment of Major Depressive Disorder(MDD)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00672659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*